Doping in Cycling

Bertrand Fincoeur is Senior Researcher at the Institute of Sports Sciences at the University of Lausanne, Switzerland. John Gleaves is Associate Professor of Kinesiology at the California State University, Fullerton, USA. Fabien Ohl is Full Professor of Sociology of Sport at the University of Lausanne, Switzerland.

Introduction, PART I: The Use and Supply of Doping Products, 1. Assessing and Explaining the Doping Prevalence in Cycling, 2. Changing Patterns of Drug Use in Professional Cycling: Implications for Anti-Doping Policy, 3. Substance Use, Anti-Doping, and Health in Amateur Cycling, 4. The Impact of Scientific Advances on Doping in Cycling, 5. Kicked Out: How Experts Are Being Deterred from Playing on the Doping Market, 6. The Peculiarities of the Market For Doping Products and the Role of Academic Physicians, PART II: Threats on Cycling and Opportunities for Anti-Doping, 7. Doped Humans and Rigged Bikes – And Why We (Wrongly) Get More Upset About the Bikes, 8. Everyone Was Doing It: Applying Lessons from Cycling’s EPO Era to a Looming TUE Era, 9. Cycling Teams Preventing Doping: Can the Fox Guard the Hen House?, 10. Blowing the Whistle on Doping in Cycling, 11. Performance Data to Improve Cycling’s Credibility?, 12. What Might a Partially Relaxed Anti-Doping Regime in Professional Cycling Look Like?, PART III: Issues, Controversies and Stakes, 13. The Decline of Trust in British Sport Since the London Olympics: Team Sky’s Fall from Grace, 14. Is Froome’s Performance on the 2015 Tour de France Credible? A Sociological Analysis of the Construction of the Performance’s Authenticity in Cycling, 15. The Clean Corrective: Can Thinking About Clean Cyclists Enhance Anti-Doping?, 16. What to do with the TUE Process? Bradley Wiggins, Therapeutic Use and Data Sharing: A Critical Analysis, 17. Doping Relevance and the World Anti-Doping Code